Drug Discovery Today 2011 v.16 №13-14

London, UK.: Elsevier. — 112 p.Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Keynote.
A molecular informatics view on best practice in multi-parameter compound optimization.
Scott J. Lusher, Ross McGuire, Rita Azevedo, Jan-Willem Boiten, Rene C. van Schaik and Jacob de Vlieg.
Particulate vaccines: on the quest for optimal delivery and immune response.
Marie-Luce De Temmerman, Joanna Rejman, Jo Demeester, Darrell J. Irvine, Bruno Gander and.
Stefaan C. De Smedt.
A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements.
Adam J. Schwarz, Lino Becerra, Jaymin Upadhyay, Julie Anderson, Richard Baumgartner, Alexandre Coimbra, Jeff Evelhoch, Richard Hargreaves, Brigitte Robertson, Smriti Iyengar, Johannes Tauscher, David Bleakman and David Borsook.
Informatics.
Electronic health records: Implications for drug discovery.
Lixia Yao, Yiye Zhang, Yong Li, Philippe Sanseau and Pankaj Agarwal.
Post screen.
A generic operational strategy to qualify translational safety biomarkers.
Katja Matheis, David Laurie, Christiane Andriamandroso, Nadir Arber, Lina Badimon, Xavier Benain,
Kaïdre Bendjama, Isabelle Clavier, Peter Colman, Hüseyin Firat, Jens Goepfert, Steve Hall, Thomas Joos, Sarah Kraus, Axel Kretschmer, Michael Merz, Teresa Padro, Hannes Planatscher, Annamaria Rossi, Nicole Schneiderhan-Marra, Ina Schuppe-Koistinen, Peter Thomann, Jean-Marc Vidal and Béatrice Molac.
Portfolio management in early stage drug discovery – a traveler’s guide through uncharted territory.
Ulrich A.K. Betz.
PLK1 as an oncology target: current status and future potential Campbell McInnes and Michael D. Wyatt.
The impact of epigenomics on future drug design and new therapies.
Christopher A. Hamm and Fabricio F. Costa.
Rendezvous in chemical space? Comparing the small molecule compound libraries of Bayer and Schering.
Jens Schamberger, Michael Grimm, Andreas Steinmeyer and Alexander Hillisch.